医学文献 >>
  • 检索发现
  • 增强检索
知识库 >>
  • 临床诊疗知识库
  • 中医药知识库
评价分析 >>
  • 机构
  • 作者
默认
×
热搜词:
换一批
论文 期刊
取消
高级检索

检索历史 清除

18F-脱氧葡萄糖正电子发射计算机断层扫描代谢参数与肺腺癌实性型和微乳头型组织学亚型的关系

The correlation between metabolic parameters in 18F-FDG PET-CT and solid and micropapillary histological subtypes in lung adenocarcinoma

摘要目的:探讨 18F-脱氧葡萄糖( 18F-FDG)正电子发射计算机断层扫描(PET-CT)代谢参数[原发病灶最大标准摄取值(SUV max)、肿瘤代谢体积(MTV)、糖酵解总量(TLG)]与肺腺癌实性型和微乳头型组织学亚型的关系及预测效能。 方法:回顾性分析145例手术切除前行 18F-FDG PET-CT检查肺腺癌患者的临床数据及影像资料。实性型和微乳头型亚型组与其他亚型组间各参数的比较采用Mann-Whitney U检验,采用受试者工作特征(ROC)曲线和曲线下面积(AUC)评估PET-CT各参数对实性型和微乳头型亚型成分的预测效能,多因素分析采用logistic回归分析。 结果:全组145例患者中,实性型和微乳头型亚型肺腺癌22例,其他亚型123例。实性型和微乳头型亚型组患者的中位SUV max和中位TLG分别为15.07和34.98,高于其他亚型组(分别为6.03和10.16,均 P<0.05)。ROC曲线显示,SUV max和TLG对预测实性型和微乳头型亚型效能较好[AUC分别为0.811(95% CI:0.715~0.907)和0.725(95% CI:0.610~0.840),均 P<0.05]。含有实性或微乳头型成分组患者的中位SUV max和中位TLG分别为11.58和22.81,高于不含实性和微乳头型成分组患者(分别为4.27和6.33,均 P<0.05)。ROC曲线分析结果显示,SUV max和TLG对预测肺腺癌病灶存在实性型或微乳头型成分效能较好[AUC分别为0.757(95% CI:0.679~0.834)和0.681(95% CI:0.595~0.768),均 P<0.05]。多因素logistic回归分析显示,临床分期(Ⅲ~Ⅳ期)、SUV max≥10.27、TLG≥7.12是肺腺癌微乳头型或实性型成分存在的独立危险因素(均 P<0.05)。 结论:肺腺癌原发灶的SUV max和TLG对微乳头型和实性型组织学成分具有较好的预测效能,尤其是在预测实性型和微乳头型为主型肺腺癌方面,并且SUV max和TLG是预测微乳头型或实性型成分存在的独立影响因素。

更多

abstractsObjective:Solid and micropapillary pattern are highly invasive histologic subtypes in lung adenocarcinoma and are associated with poor prognosis while the biopsy sample is not enough for the accurate histological diagnosis. This study aims to assess the correlation and predictive efficacy between metabolic parameters in 18F-fluorodeoxy glucose positron emission tomography/computed tomography ( 18F-FDG PET-CT), including the maximum SUV (SUV max), metabolic tumor volume (MTV), total lesion glycolysis (TLG) and solid and micropapillary histological subtypes in lung adenocarcinoma. Methods:A total of 145 resected lung adenocarcinomas were included. The clinical data and preoperative 18F-FDG PET-CT data were retrospectively analyzed. Mann-Whitney U test was used for the comparison of the metabolic parameters between solid and micropapillary subtype group and other subtypes group. Receiver operating characteristic (ROC) curve and areas under curve (AUC) were used for evaluating the prediction efficacy of metabolic parameters for solid or micropapillary patterns. Univariate and multivariate analyses were conducted to determine the prediction factors of the presence of solid or micropapillary subtypes. Results:Median SUV max and TLG in solid and papillary predominant subtypes group (15.07 and 34.98, respectively) were significantly higher than those in other subtypes predominant group (6.03 and 10.16, respectively, P<0.05). ROC curve revealed that SUV max and TLG had good efficacy for prediction of solid and micropapillary predominant subtypes [AUC=0.811(95% CI: 0.715~0.907) and 0.725(95% CI: 0.610~0.840), P<0.05]. Median SUV max and TLG in lung adenocarcinoma with the solid or micropapillary patterns (11.58 and 22.81, respectively) were significantly higher than those in tumors without solid and micropapillary patterns (4.27 and 6.33, respectively, P<0.05). ROC curve revealed that SUV max and TLG had good efficacy for predicting the presence of solid or micropapillary patterns [AUC=0.757(95% CI: 0.679~0.834) and 0.681(95% CI: 0.595~0.768), P<0.005]. Multivariate logistic analysis showed that the clinical stage (Stage Ⅲ-Ⅳ), SUV max ≥10.27 and TLG≥7.12 were the independent predictive factors of the presence of solid or micropapillary patterns ( P<0.05). Conclusions:Preoperative SUV max and TLG of lung adenocarcinoma have good prediction efficacy for the presence of solid or micropapillary patterns, especially for the solid and micropapillary predominant subtypes and are independent factors of the presence of solid or micropapillary patterns.

More
广告
  • 浏览96
  • 下载0
中华肿瘤杂志

中华肿瘤杂志

2022年44卷6期

555-561页

MEDLINEISTICPKUCSCDCA

加载中!

相似文献

  • 中文期刊
  • 外文期刊
  • 学位论文
  • 会议论文

加载中!

加载中!

加载中!

加载中!

扩展文献

法律状态公告日 法律状态 法律状态信息

特别提示:本网站仅提供医学学术资源服务,不销售任何药品和器械,有关药品和器械的销售信息,请查阅其他网站。

  • 客服热线:4000-115-888 转3 (周一至周五:8:00至17:00)

  • |
  • 客服邮箱:yiyao@wanfangdata.com.cn

  • 违法和不良信息举报电话:4000-115-888,举报邮箱:problem@wanfangdata.com.cn,举报专区

官方微信
万方医学小程序
new医文AI 翻译 充值 订阅 收藏 移动端

官方微信

万方医学小程序

使用
帮助
Alternate Text
调查问卷